White Paper

Solving Cost And Supply Challenges In Biopharma Downstream Processing

Source: Avantor

By Nandu Deorkar, Ph.D., MBA, Senior Vice President, Research & Development — Biopharma Production, Avantor

GettyImages-1322996506 Capital Equipment In Lab

Today monoclonal antibodies (mAbs) represent the largest sector of the biopharmaceutical market. This brings about concerns for the costs of downstream processing, which accounts for roughly 60 percent of the cost of producing a biologic drug and often takes place over a period of week. Of downstream processes, buffer management and chromatographic purification operations are the primary areas being reconsidered for an innovative upgrade.

Find out where these two areas are currently showing inefficiencies, and explore data-driven solutions in areas where there is room for change and enhancements.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online